Kiniksa Pharmaceuticals International, plc KNSA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's total equity?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported total equity of $605.69M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's total equity changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's total equity increased by 32.4% year-over-year, from $457.49M to $605.69M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total equity?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's total equity has grown at a 12.7% compound annual growth rate (CAGR), from $311.94M to $567.61M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.